Use and cost of antiretrovirals in France 1995-2000: An analysis based on the medical dossier on human immunodeficiency (release 2) database

PharmacoEconomics

Volumn 22, Issue 16, 2004, Pages 1061-1070

  Flori, Yves A ^a,b,c   Le Vaillant, Marc ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Inst Sante Pub d'Epidemiol Devmt   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COST UTILITY ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG COST; DRUG USE; DRUG UTILIZATION; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; LYMPHOCYTE COUNT; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; ECONOMICS, HOSPITAL; FRANCE; HIV INFECTIONS; HOSPITALIZATION; HUMANS;

EID: 10044289283     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422160-00003     Document Type: Article

References (26)

1. Ministère de l'emploi et de la solidarité. Les chiffres clés: sida et hépatite C. Paris: Flammarion Médecine- Science, 1999
2. Anis AH, Hoggs RS, Wang X, et al. Modelling the potential economic impact of viral-load driven drug combination antiretroviral drug therapy. Pharmacoeconomics 1998; 13: 697-705
3. Chatterton ML, Scott-Lennox J, Wu AW, et al. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection. Pharmacoeconomics 1999; 15 Suppl. 1: 67-74
4. Lacey L, Hopkinson PK, Montaner J, et al. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV Infection. Pharmacoeconomics 1999; 15 Suppl. 1: 55-66
5. Youle M, Trueman P, Simpson K. Health economics in HIV disease: a review of the European literature. Pharmacoeconomics 1999; 15 Suppl. 1: 1-12
6. Richter A, Brandeau M, Owens D. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus in injection drugs users and non-users. Med Decis Making 1999; 19: 167-79
7. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31
8. Beck EJ, Tolley K, Power A, et al. The use and cost of HIV service provision in England in 1996. Pharmacoeconomics 1998; 13: 639-52
9. Beck EJ, Flori YA, Geofard PY, et al. Uptake of combination antiretroviral therapy during 1996 and 1997: an Anglo-French comparison. [Abstract 42289] 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva. IAS, 1998
10. Anis AH, Hogg RS, Yip B, et al. Average annual drug cost and its determinants in a population based cohort of HIV positive adult men and women. Pharmacoeconomics 1998; 13: 327-36
11. Carpenter CCJ, Cooper DA, Fishl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society, USA Panel. JAMA 2000; 283: 381-90
12. Delfraissy JF, editor. Prise en charge thérapeutique des personnes infectées par le VIH. Paris : Ministère de l'emploi et de la solidarité, 1999, 2000
13. Beck EJ, Miners AH, Tolley K. The Cost of HIV treatment and care: a global review. Pharmacoeconomics 2001; 19: 13-59
14. Kerleau M, Le Vaillant M, Flori YA. Measuring the variability of prescription use in patients with HIV infection or AIDS. Pharmacoeconomics 1997; 12: 246-61
15. Beck EJ, Mandalia S, Williams L, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. AIDS 1999; 13: 2157-64
16. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. Fédération Nationale des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101-5
17. Lavalle C, Aguilar JC, Peña F, et al. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res 2000; 31: 515-9
18. Velasco M, Gómez A, Fernández C, et al. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Med 2000; 1: 246-51
19. Floridia M, Massella M, Bucciardini R, et al. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm3). HIV Clin Trials 2000; 1: 9-16
20. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-9
21. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 2001; 13: 733-41
22. Bidwell Goetz M, Morreale AP, Rhew DC, et al. Effect of highly active antiretroviral therapy on outcomes in Veterans Affairs Medical Centers. AIDS 2001; 15: 530-2
23. Kyriopoulos JE, Geitona MA, Paparizos VA, et al. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece. J Med Syst 2001; 25: 73-80
24. Dormont J, editor. Prise en charge thérapeutique des personnes infectées par le VIH. Paris: Ministère de la santé, 1997
25. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997
26. Tolley K, Gyldmark M. The treatment and care cost of people with HIV infection or AIDS: development of a standardised cost framework for Europe. Health Policy 1993; 24: 55-70